Prime Medicine, Inc. Common Stock (PRME)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $932.06M
Last updated: Nov 17, 2026 at 4:31 PM ET
Prime Medicine, Inc. Common Stock (PRME) Statistics
Prime Medicine, Inc. Common Stock (PRME) has a market cap of $932.06M and an enterprise value of $877.17M. It kept -2497.56% of revenue as net income over the last 12 months. Its share count is up 10.81% from a year earlier.
Total Valuation
Enterprise value is 5.89% below the market cap, as cash exceeds debt.
| Market Cap | $932.06M |
|---|---|
| Enterprise Value | $877.17M |
| Latest price (Nov 17, 2026) | $3.84 |
Key Dates
The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 96.7x and 80.9x. Its year-end P/S ranged from 33.6x to 346.7x from 2022 to 2025.
| P/S Ratio | 96.7x |
|---|---|
| Forward P/S | 121.2x |
| P/B Ratio | 80.9x |
Price Statistics
The stock is up 13.95% over 52 weeks and trades 3.50% above its 50-day average.
| Beta (1Y) | 2.46 |
|---|---|
| 52-Week Change | +13.95% |
| 1-Month Change | +0.26% |
| 3-Month Change | +8.47% |
| 6-Month Change | +42.22% |
| Total Return (1Y) | +13.95% |
| Total Return (3Y CAGR) | -16.51% |
| Return vs SPY (1Y) | -3.39% |
| Max Drawdown (1Y) | -42.25% |
| Max Drawdown (3Y) | -87.96% |
| Sharpe Ratio (1Y) | 0.09 |
| Correlation with SPY (1Y) | 0.38 |
| 50-Day Average | $3.71 |
| 200-Day Average | $3.51 |
| 52-Week Range | $2.67 to $5.91 |
| RSI (14 Days) | 46.8 |
| Average Volume (20 Days) | 6.04M |
Financial Position
Current assets cover 1.79x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.79x |
|---|---|
| Quick Ratio | 1.79x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -2090.23% and return on assets is -82.46% over the last 12 months.
| Return on Equity (ROE) | -2090.23% |
|---|---|
| Return on Assets (ROA) | -82.46% |
| ROA (5Y Average) | -63.07% |
| Asset Turnover | 0.02x |
Scores
PRME has an Altman Z-Score of -7.26, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -7.26 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $7.06M over the last 12 months is up 18.14% from the 12 months before.
| Revenue | $7.06M |
|---|---|
| Revenue Growth (YoY) | +18.14% |
| Gross Profit | $7.06M |
| Operating Income | -$182.47M |
| Pretax Income | -$176.35M |
| Net Income | -$176.35M |
| EBITDA | -$174.25M |
| Reported EPS (TTM) | -$0.98 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 3.95% of the $213.85M in total assets.
| Cash and Equivalents | $54.89M |
|---|---|
| Total Debt | $0 |
| Net Cash | $54.89M |
| Net Cash Per Share | $0.31 |
| Working Capital | $28.06M |
| Shareholder Equity | $8.44M |
| Book Value Per Share | $0.05 |
| Total Assets | $213.85M |
| Total Liabilities | $205.42M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $848.00K of capital spending, operating cash flow left -$158.54M of free cash flow.
| Operating Cash Flow | -$157.69M |
|---|---|
| Capital Expenditures | $848.00K |
| Free Cash Flow | -$158.54M |
| FCF Per Share | -$0.87 |
| Depreciation and Amortization | $9.00M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2584.24%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -2584.24% |
| Pretax Margin | -2497.56% |
| Net Margin | -2497.56% |
| EBITDA Margin | -2467.74% |
| FCF Margin | -2245.33% |
Growth
| Revenue Growth (5Y CAGR) | -2.32% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -22.89% |
| Tangible Book Per Share Growth (2Y CAGR) | -22.89% |
Dividends and Yields
PRME does not pay a dividend. Its free cash flow yield is -23.21%.
| FCF Yield | -23.21% |
|---|---|
| Buyback Yield | -0.43% |
| Shareholder Yield | -0.43% |
Peer Position
Against 7 similar companies, PRME has the highest P/S.
P/S RatioPeer median 5.4x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -8.07%
| P/S Ratio | 96.7x vs 5.4x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +18.14% vs -8.07% median |
Analyst Forecast
Consensus estimates put revenue growth at 52.55% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +52.55% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About PRME
What is PRME's market cap?
Prime Medicine, Inc. Common Stock has a market cap of $932.06M. Its enterprise value, which adds debt and subtracts cash, is $877.17M.
How many shares of PRME are outstanding?
Prime Medicine, Inc. Common Stock has 177.86M shares outstanding. The count is up 10.81% from a year earlier.
Does PRME pay a dividend?
No. Prime Medicine, Inc. Common Stock does not pay a dividend.
How much debt does PRME have?
Prime Medicine, Inc. Common Stock has $0 of total debt and $54.89M of cash and equivalents, a net cash position of $54.89M.
PRME pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors